Pan-Canadian Pharmaceutical Alliance: No pCPA Negotiations

As of February 29, 2016

There are 39 drug products for which the pCPA has decided **not to negotiate** collectively or individually at the provincial-territorial level:

Drug Product Brand Name (Generic Name)	Indication/Use
Abilify (aripiprazole)	Used to treat major depressive disorder
Afinitor (everolimus)	Used to treat renal angiomyolipoma
Afinitor (everolimus)	Used to treat subependymal giant cell astrocytoma associated with tuberous sclerosis complex
Aloxi (palonosetron)	Used to prevent chemotherapy-induced nausea and vomiting
Aloxi IV (palonosetron)	Used to prevent chemotherapy-induced nausea and vomiting
Apprilon (doxycycline)	Used to treat inflammatory rosacea
Arzerra (ofatumumab)	Used to treat chronic lymphocytic leukemia
Benlysta (belimumab)	Used to treat lupus
Bystolic (nebivolol)	Used to treat hypertension
Constella (linaclotide)	Used to treat irritable bowel syndrome with constipation
Dymista (azelastine/fluticasone)	Used to treat seasonal allergic rhinitis
Edarbi (azilsartan)	Used to treat high blood pressure
Edarbyclor (azilsartan/chlorthalidone)	Used to treat high blood pressure
Elelyso (taliglucerase alfa)	Used to treat Gaucher disease
Erbitux (cetuximab)	Used in combination with FOLFIRI for first-line treatment of KRAS wild type metastatic colorectal cancer
Fampyra (fampiridine)	Used to treat Multiple Sclerosis
Grastek (timothy grass standardized allergenic extract)	Used to treat grass pollen-induced allergic rhinitis
Intuniv XR (guanfacine hydrochloride)	Used to treat attention deficit hyperactivity disorder
Juxtapid (lomitapide)	Used to treat homozygous familial hypercholesterolemia
Kazano (alogliptin/metformin)	Used to treat Type 2 diabetes
Nesina (alogliptin)	Used to treat Type 2 diabetes
Neupro (rotigotine)	Used to treat idiopathic Parkinson disease
Nexavar (sorafenib)	Used to treat progressive differentiated thyroid carcinoma
Otezla (apremilast)	Used to treat moderate to severe plaque psoriasis
Perjeta (pertuzumab)	Use to treat neoadjuvant breast cancer
Perjeta-Herceptin Combo Pack (pertuzumab)	Use to treat neoadjuvant breast cancer
Picato (ingenol mebutate)	Used to treat actinic keratosis
Revolade (eltrombopag)	Used to treat thrombocytopenia in patients with chronic hepatitis C infection
Samsca (tolvaptan)	Used to treat hyponatremia

Drug Product Brand Name (Generic Name)	Indication/Use
Signifor (pasireotide)	Used to treat Cushing Disease
Soliris (eculizumab)	Used to treat aHUS
Stelara (ustekinumab)	Used to treat psoriatic arthritis
Stivarga (regorafenib)	Used to treat metastatic colorectal cancer
Sublinox (zolpidem)	Used to treat acute insomnia
Tykerb (lapatinib)	Used in combination with letrozole to treat metastatic breast cancer
Vimizim (elosulfase)	Used to treat mucopolysaccharidosis IVA (MPS IVA)
Xiaflex (collagenase clostridium histolyticum)	Used to treat Dupuytren's contracture
Zaltrap (aflibercept)	Used to treat metastatic colorectal cancer
Zykadia (ceritinib)*	Used to treat ALK+ non-small cell lung cancer

*New drug product since last update of January 31, 2016.

Each drug product is considered individually based on a number of factors, including the recommendation from the Canadian Drug Expert Committee (CDEC) or the pan-Canadian Oncology Drug Review Expert Review Committee (pERC), patient perspective, clinical need and considerations. The majority of products for which the pCPA and the provinces and territories do not pursue negotiations have received negative recommendations from CDEC or pERC due to clinical concerns, such as uncertainty regarding the clinical benefit of the drug product. If new information becomes available to address the concerns raised by pCPA and the applicable national review committee, the pCPA may reconsider their decision.